<DOC>
	<DOCNO>NCT00028431</DOCNO>
	<brief_summary>This study determine efficacy melanoma vaccine chemotherapy cocktail compose CTLA-4 antibody ; tyrosinase , gp100 , MART-1 peptide ; incomplete Freund 's adjuvant ( IFA ) without interleukin-12 patient resect stage III IV melanoma .</brief_summary>
	<brief_title>Novel Adjuvants Peptide-Based Melanoma Vaccines</brief_title>
	<detailed_description>In Phase I/II trial , patient resect stage III IV melanoma render free disease , high risk relapse , treat peptides/IFA dose 0.5 mg peptide plus CTLA-4 antibody give intravenously , 3 mg/kg , vaccination . In Phase II randomize study , patient treat melanoma peptide vaccine alone , CTLA-4 antibody , CTLA-4 antibody combine IL-12 30 ng/kg alum . The peptides tyrosinase 368-376 ( 370D ) ; gp100 209-217 ( 210M ) ; MART-1 26-35 ( 27L ) emulsify IFA . The dosing schedule trial 1 , 2 , 3 , 4 , 5 , 6 month ; 9 12 total 8 vaccination .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Inclusion criterion : Diagnosis stage III IV cutaneous , mucosal , ocular melanoma Completely resect disease diseasefree HLAA2.1 positive Tumor tissue available immunohistochemical analysis stain positive least 1 specified antigen At least 1 month since prior therapy cancer , include radiotherapy adjuvant therapy WBC count least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 gm/dL Creatinine great 2.0 mg/dL Bilirubin great 2.0 mg/dL SGOT/SGPT great 2.5 time upper limit normal ECOG performance status 01 Have fail alphainterferons ( patient resect stage III disease ) Exclusion criterion : Prior treatment tyrosinase : 368376 ( 370D ) , gp100:209217 ( 210M ) , MART1:2635 ( 27L ) peptide Steroid therapy immunosuppressive medication requirement Major systemic infection ( e.g. , pneumonia sepsis ) Coagulation bleed disorder Major medical illness gastrointestinal , cardiovascular , respiratory system Allergic reaction Montanide ISA 51 ( incomplete Freund 's adjuvant ) History uveitis autoimmune inflammatory eye disease Other active autoimmune disease Positive hepatitis B surface antigen , hepatitis C antibody , HIV antibody Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Stage III melanoma</keyword>
	<keyword>Stage IV melanoma</keyword>
	<keyword>Interleukin-12</keyword>
	<keyword>Cancer Vaccines</keyword>
	<keyword>Antineoplastic Agents , Combined</keyword>
	<keyword>Incomplete Freund 's adjuvant</keyword>
	<keyword>Monophenol Monooxygenase</keyword>
	<keyword>Mannitol</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Melan-A Protein</keyword>
	<keyword>Antigens , Neoplasm</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Melanocyte lineage-specific antigen gp100</keyword>
	<keyword>CTLA-4</keyword>
</DOC>